We are live on ! Find out more
RNAZ icon

TransCode Therapeutics
RNAZ

1 hedge funds and large institutions have $5.98M invested in TransCode Therapeutics in 2021 Q4 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

0% more funds holding

Funds holding: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (0%)

18% less capital invested

Capital invested by funds: $7.28M → $5.98M (-$1.3M)

Holders
1
Holders Change
–
Holders Change %
0%
% of All Funds
0.02%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$271K
2
Two Sigma Investments
Two Sigma Investments
New York
-$229K
3
TSS
Two Sigma Securities
New York
-$100K
4
BRWA
B. Riley Wealth Advisors
Florida
-$75K
5
VF
Virtu Financial
New York
-$54K
Name Holding Trade Value Shares
Change 		Change in
Stake
ACM
1
AIGH Capital Management
Maryland
$3.23M – – –
KC
2
Kepos Capital
New York
$762K – – –
WVP
3
Worth Venture Partners
New Jersey
$751K – – –
Vanguard Group
4
Vanguard Group
Pennsylvania
$508K – – –
RAM
5
Redmond Asset Management
Virginia
$224K – – –
Geode Capital Management
6
Geode Capital Management
Massachusetts
$181K – – –
ACM
7
ACT Capital Management
Pennsylvania
$127K – – –
State Street
8
State Street
Massachusetts
$52K – – –
BlackRock
9
BlackRock
New York
$43K – – –
KJHP
10
K.J. Harrison & Partners
Ontario, Canada
$41K – – –
SC
11
Shay Capital
New York
$38K – – –
UBS Group
12
UBS Group
Switzerland
$13K – – –
HNWAG
13
High Net Worth Advisory Group
Florida
$6K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$6K – – –
BRWA
15
B. Riley Wealth Advisors
Florida
– -$75K – –
Citadel Advisors
16
Citadel Advisors
Florida
– -$271K – –
Two Sigma Investments
17
Two Sigma Investments
New York
– -$229K – –
TSS
18
Two Sigma Securities
New York
– -$100K – –
VF
19
Virtu Financial
New York
– -$54K – –

RNAZ Hedge Fund Activity: Q4 2021 in Review

1 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in TransCode Therapeutics (RNAZ) for Q4 2021, worth a combined $5.98M — down 18% from $7.28M a quarter earlier.

Fund positioning in RNAZ was balanced in Q4 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.

The largest seller was Citadel Advisors, cutting an estimated $271K.

  • 1 institutional investor held TransCode Therapeutics (RNAZ) as of Q4 2021, unchanged from Q3 2021.
  • Funds reported $5.98M of TransCode Therapeutics stock for Q4 2021, down 18% quarter-over-quarter.
  • 0 funds opened new TransCode Therapeutics positions in Q4 2021 and 0 closed out.
  • The largest TransCode Therapeutics seller in Q4 2021 was Citadel Advisors, an estimated $271K sold.

Based on aggregated 13F filings for Q4 2021.